What made Incyte rise last week?
This article was originally published in Scrip
The discontinuation of Sanofi's JAK2 inhibitor for myelofibrosis, fedratinib (SAR302503), despite previous positive results from Phase III trials was a shock to many on 18 November. As might be expected, the elimination of impending competition was seen as a boon for the maker of the only approved JAK inhibitor for myelofibrosis, Incyte (which together with Novartis sells Jakafi/Jakavi (ruxolitinib).
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.